Skip to main content
Download PDF

Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study

BMC Infectious Diseases volume 24, Article number: 198 (2024) Cite this article

Abstract

Background

Drug-resistant tuberculosis (DR-TB) is a major public health threat in Hunan Province, with an increasing clinical burden in recent years. This study aimed to identify socio-demographic and clinical factors associated with DR-TB in Hunan province, China.

Methods

A case-control study was conducted in Hunan province. Cases were all DR-TB patients who were confirmed by culture and Drug susceptibility testing (DST) and enrolled at the DR-TB treatment center of Hunan Chest Hospital from 2013 to 2018. Controls were all Drug Susceptible TB (DS-TB) patients confirmed by DST and enrolled at the same hospital during the same period. A multivariable logistic regression model was fitted to identify factors significantly associated with DR-TB.

Results

A total of 17,808 patients (15,534 DS-TB controls and 2274 DR-TB cases) were included in the study, with a mean age of 42.5 years (standard deviation (SD) ± 17.5 years) for cases and 46.1 years (SD ± 19.1 years) for controls. Age 15-64 years (Adjusted odds ratio (AOR = 1.5, 95% CI; 1.4, 1.8)), ethnic minorities (AOR = 1.5; 95% CI; 1.4, 1.8), and a history of previous TB treatment (AOR) = 1.84; 95% CI: 1.57, 2.15) was significantly associated with DR-TB. Being resident in a province outside Hunan was also a significant risk factor (AOR = 1.67; 1.27, 2.21) for DR-TB.

Conclusion and recommendations

To prevent the occurrence of DR-TB in Hunan Province, interventions should be targeted at high-risk demographic groups such as ethnic minorities, individuals of productive age, and residents living outside the province. Interventions must also be targeted to previously treated cases, suggesting the appropriateness of diagnosis, treatment, and follow-up. Understanding the risk factors at the province level helps design strategies for controlling DR-TB due to variations by socioeconomic differences, quality of health care, and healthcare access.

Peer Review reports

Introduction

Drug-resistant tuberculosis (DR-TB) is defined as tuberculosis (TB) that is resistant to at least one first-line anti-TB drug (Isoniazid, Rifampicin, Ethambutol, Pyrazinamide, and Streptomycin or any second-line drugs or second-line drugs (including fluoroquinolones and aminoglycosides) or both [1]. DR-TB can occur due to genetic mutations or drug-resistant strains’ transmission [2].

The global burden of DR-TB has increased in the last two decades, with nearly half a million people developing DR-TB every year [1]. It becomes a major challenge to achieving the global End-TB Strategy targets [3]; according to the 2022 WHO global TB report, there were an estimated 450,000 DR-TB cases in 2021 [4]. Nearly half of DR-TB cases were reported in India (26%), the Russian Federation (8.5%), and Pakistan (7.9%) [4].

The Western Pacific region has the third highest burden of TB among WHO global regions (accounting for 18% of cases), next to South-East Asia (43%) and Africa (25%) regions. About 86-90% of the global DR-TB burden is from 30 high-DR-TB burden countries [4], and China is among the 30 high-DR-TB burden countries globally. A study in Huna province among pulmonary TB cases showed that 40.9% of patients were resistant to at least one of the first-line anti-TB drugs [5].

Clinical factors such as a previous history of TB treatment and comorbidities, including Diabetics Mellitus, Human Immunodeficiency Virus infection, and Chronic Obstructive Pulmonary Disease, were identified as risk factors of DR-TB [6]. A systematic review showed that factors such as baseline smear positivity, interruption of treatment, non-adherence, having an adverse drug reaction, being aged > 40 years, being unemployed, and lack of health insurance were significantly associated with the occurrence of DR-TB [7]. Moreover, a contact history with a known TB patient and a previous history of TB treatment failure was associated with a higher risk of developing DR-TB [8]. However, evidence on risk factors of DR-TB in high burden settings such as Hunan province is limited.

Despite significant investments in TB control and treatment strategies in China, TB and DR-TB remain major public health threats in Hunan Province with an increasing disease burden in recent years. Identifying risk factors of DR-TB may aid in designing effective control strategies in the province and other endemic areas. Therefore, this study aims to identify clinical and demographic risk factors associated with DR-TB in Hunan Province.

Methods

Study area

This study was conducted in Hunan province, located in South-Central China. Hunan is China’s 7th most populous province with more than 66 million people in 2020 [9]. Hunan Chest Hospital is the largest chest hospital in Hunan Province, located in Changsha City, the province’s capital. It has more than 600 beds and provides services for diagnosing and treating TB and DR-TB. The hospital’s DR-TB treatment center was established in 2011.

Study design and data sources

A case-control study was conducted to identify the risk factors of DR-TB. All patients diagnosed with DS-TB and DR-TB (Pulmonary vs extrapulmonary, childhood vs adult, bacteriologically confirmed vs clinically diagnosed, and new vs previously treated) in Hunan Chest Hospital from 2013 to 2018 were included in the study. Cases were all DR-TB patients who were confirmed by culture and Drug Susceptibility Testing (DST), enrolled at the DR-TB treatment center of Hunan Chest Hospital, from 2013 to 2018. Controls were all DS-TB patients who were confirmed by DST and enrolled at the same hospital during the same period. Data were obtained from an internet-based TB management information system TB control institute of Hunan province, DR-TB medical records, and DST registration books. Information obtained from the different data sources is linked using patients’ identification. DR-TB is among the notifiable diseases in China, routinely collected by health professionals and notified to the Chinese Center for Disease Control and Prevention (CDC). All DST- and DR-TB patients registered from 2013 to 2018 were included in the analysis. However, patients with unknown drug susceptibility (DST-TB vs DR-TB) status were excluded from the study.

DS-TB and DR- TB diagnosis

Hunan’s TB institutions follow WHO recommendations for TB diagnosis; using sputum smear microscopy, clinical assessment based on symptoms, sputum culture, and molecular detection. There are 131 counties in Hunan province and only 32 counties can provide comprehensive diagnostic services including culture. In Hunan Chest Hospital, drug susceptibility testing (DST) is mainly carried out in the diagnosis of DR-TB. As a result, sputum specimens from all culture-positive TB patients from throughout the province are referred to the Hunan Chest Hospital for DST. In the hospital, phenotypic DST based on solid and liquid culture techniques, and molecular methods using line probe assays as well as Xpert® MTB/RIF are performed. At the Hunan Chest Hospital, DST is performed for rifampicin, isoniazid, ethambutol, streptomycin, kanamycin, and ofloxacin. Solid and liquid culture are used for the follow-up of patient’s progress and treatment outcomes.

Variables

The dependent variable of the study was DR-TB status (i.e., DR-TB as cases and DS-TB as controls). DR-TB was defined as resistance to at least one first-line or secondline TB drugs. The independent variables were demographic factors such as age, sex, occupational status, residence type, ethnicity, year of enrolment, and institution type where the diagnosis was made as well as clinical factors such as history of TB treatment and registration type.

Data analysis

A bivariable logistic regression model was fitted and variables with a P-value < 0.2 were selected for inclusion in a multivariable model, to identify factors significantly associated with DR-TB. Adjusted odds ratios (AOR) with 95% confidence intervals (CI) were calculated to quantify the association between the dependent and independent variables and a p-value of < 0.05 was used to declare statistical significance. The data were analysed using Stata version 17 software.

Results

Sociodemographic characteristics

In Hunan Chest Hospital a total of 318,795 patients were registered for Tuberculosis (TB) between 2013 and 2018. Of these, 300,962 patients were excluded from the analysis due to their unknown outcome status. Moreover, an additional 25 participants (three simple tuberculosis pleurisy and 22 extrapulmonary cases) were excluded. Finally, a total of 17,808 (15,534 DS-TB controls and 2274 DR-TB cases) were included in the final analysis. The remaining (Fig. 1). The mean age of respondents was 42.5 with a standard deviation (SD) of 17.5 for cases and 46.1 years with an SD of 19.1 years for controls. Slightly lower than a quarter of cases (23.9%) and nearly a quarter of controls (26.0%) were female. Around one-fifth (n = 448, 19.7%) of cases and controls (n = 2868, 18.5%) were under the age of 25 years. Most cases (n = 2130, 93.7%) and controls (n = 14,868, 95.7%) were Han by ethnicity. The majority, 77.1% (n = 1753) of cases and 77.7% (n = 12,066) of controls were farmers by occupation. Most participants, including 2092 (92.0%) cases and 14,523 (93.5%) controls, were from Hunan province. The majority, 1813 (79.9%) cases, and 12,379 (80.6%) controls were diagnosed by the Centre for Disease Control. A previous history of TB treatment was reported in 614 (27.0%) cases and 2084 (13.4%) controls (Table 1).

Fig. 1
figure 1

Flowchart of patient record selection process

Full size image
Table 1 Socio-demographic and clinical characteristics of study participants in Hunan Province, China, 2013 to 2018
Full size table

Risk factors for DR-TB in Hunan, China

In the bivariable analysis, age, gender, residence, occupation, ethnicity, and treatment category were selected using a p-value threshold of < 0.2. Current residency status, age, ethnicity, and treatment category were statistically significant in the multivariable analysis at a p-value of < 0.05. Occupation was removed in the multivariable analysis due to multicollinearity. The odds of DR-TB among productive age groups (i.e., 15-64 years) were nearly 50% higher than under 15 and elderly (> = 65) populations (AOR = 1.5; 95% CI: 1.4, 1.8). Other ethnic minorities had nearly 50% higher odds of developing DR-TB than Han majorities (AOR = 1.5; 95% CI: 1.2, 1.8). The odds of DR-TB among residents of neighboring provinces were significantly higher compared with those of Hunan residents (AOR = 1. 7; 95% CI: 1.4, 2. 1). Similarly, the odds of DR-TB in previously treated cases were nearly two times higher than in the new treatment category (AOR = 2.3; 95% CI: 2.1, 2.6). The Hosmer and Leme show goodness of fit test showed the model was adequately fitted (P-value = 0.12) (Table 2).

Table 2 Factors associated with DR-TB in Hunan, China
Full size table

Discussion

This case-control study identified risk factors of DR-TB in Hunan province. Clinical factors such as a previous history of TB treatment were identified as a significant risk factor for DR-TB (relative to DS-TB). Moreover, demographic factors such as ethnic minorities, productive age group, and residency status outside Hunan province were identified as risk factors for DR-TB.

The finding of the previous history of TB treatment to be associated with a higher risk of DR-TB is consistent with previous studies conducted in China [10, 11], India [12], a multicenter study from eight countries [13], Pakistan [14, 15], Brazil [16, 17], Northwest Ethiopia [18,19,20], United Kingdom [10], Saudi Arabia [21] and South Africa [22]. The current finding is also in agreement with a systematic review and meta-analysis conducted in Europe [23], and a global systematic review and meta-analysis [24].

Ethnic minorities were at a higher odd of developing DR-TB compared with the Han majority. The finding agrees with studies conducted to assess health inequality in Europe and the United States, which showed that ethnic minorities had poorer health outcomes than ethnic majorities [25,26,27]. Possible reasons for this discrepancy may include poor treatment adherence to TB treatment and significant ethnic health inequalities arising from the interplay between ethnicity, spatial disparities, and socioeconomic status among different ethnic groups [26].

Productive age groups (i.e.,15-64 years) were at a higher risk of experiencing DR-TB. This finding is in line with a multicenter study conducted in South Korea [28], Brazil [17], Bangladesh [29], China [30], and United States [30]. The second possible justification could be productive population group was at a higher risk of poor treatment adherence or interruption of TB treatment due to work or travel [31].

In this study, residency outside of Hunan province was positively associated with DR-TB risk. This finding is in line with a study conducted in Hong Kong [31]. The possible reason could be residents from other provinces are classified as internal migrants according to the hukou system, a household registration system in China that permits a permanent resident for a single address issued by the government of China to each family member given at birth or by employment in the formal sectors [32]. The hukou system allows each family member to have essential access to public services, education, health services, social benefits, and job recruitment by the governmental or private sectors [33].

However, inconsistent evidence has been found concerning residency status, with some previous studies showing that residents from permanent residents were at a higher risk of developing DR-TB compared with residents from another province [34]. Similarly, a study conducted in Shanghai, China among migrants and permanent residents revealed that the transmission rate of DR-TB was higher among permanent residents than temporary migrants and residents from the local province [35].

The difference would be the higher population density in Shanghai (21,700/km2) [36] compared with the population density in Hunan province (326.27/km2) [37]. Moreover, the high cost of rent in Shanghai results in living in a condensed environment that further increases the risk of developing primary resistance [36]. Furthermore, most migrants were from rural areas, which are characterized by less cost of life and less condensed areas that will decrease the risk of acquiring drug-resistant tuberculosis.

While this study identified individual-level risk factors associated with DR-TB in Hunan province using a large sample size, it has several limitations. First, as the study was conducted using secondary data, possible important determinants such as behavioral factors (e.g., cigarette smoking and alcohol drinking) and clinical factors including adherence, baseline smear status, and time of culture conversion were not assessed. Moreover, due to the nature of the study design (i.e., hospital-based case-control study) selection bias might have been introduced. For instance, the study lacks generalizability to the general population as cases and controls were drawn purposively from the hospital. Of 318,795 TB patients, only 17,831 had DST result and were included in the study. As a result, the finding lacks external validity and will not be generalizable to TB patients in Hunan Province. The study may also be liable to recall bias and some misclassifications in the exposure and outcome status. The study also lacks drug-resistant profile of patients due to the secondary nature of the data.

The clinical burden of DR-TB is increasing over time worldwide and most countries have not achieved the END-TB WHO targets. Even though some studies on determinants of DR-TB have been conducted, the evidence on risk factors remains limited, particularly in Hunan province and other parts of China. The current study provides some clues as to the most important risk factors for DR-TB in Hunan province. The risk factors we identified are potential targets for intervention – for example, healthcare providers could focus more on patients having a previous history of TB treatment.

Conclusion

To prevent the occurrence of DR-TB in Hunan Province, interventions should be targeted at high-risk demographic groups such as individuals in productive age, ethnic minorities, and residents living outside the province. Moreover, interventions must also be targeted to previously treated cases, suggesting the appropriateness of diagnosis, treatment, follow-up, and monitoring. Understanding risk factors of DR-TB in Hunan Province, China is important in designing strategies for controlling DR-TB due to variations of health care access, socio-economic variations, and quality health care. Strengthening the existing surveillance system and improving health care access are required for proper diagnosis and treatment of DR-TB.

Availability of data and materials

Data will be available upon request from the corresponding author.

Abbreviations

AOR:

Adjusted Odds Ratio

CDC:

Centre for Disease Control

CI:

Confidence Interval

DR-TB:

Drug-resistant Tuberculosis

DST:

Drug Susceptibility Testing

DS-TB:

Drug Susceptibility Tuberculosis

INH:

Isoniazid

R:

Rifampicin

SD:

Standard Deviation

TB:

Tuberculosis

US:

United States

WHO:

World Health Organization

References

  1. World Health Organization, Global tuberculosis report. 2021.

    Google Scholar 

  2. David HL. Probability distribution of drug-resistant mutants in unselected populations of mycobacterium tuberculosis. Appl Microbiol. 1970;20:810–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. WHO. Global Tuberculosis Control SURVEILLANCE, PLANNING, FINANCING. Switzerland: WHO Press; 2008.

    Google Scholar 

  4. World Health Organization, Global tuberculosis report. 2022.

    Google Scholar 

  5. Zhao L-l, Chen Y, Chen Z-n, Liu H-c, Hu P-l, Sun Q, et al. Prevalence and molecular characteristics of drug-resistant mycobacterium tuberculosis in Hunan, China. Antimicrob Agents Chemother. 2014;58(6):3475–80.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rumende CM. Risk factors for multidrug-resistant tuberculosis. Acta Med Indones. 2018;50(1):1–2.

    PubMed  Google Scholar 

  7. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW, Baya B, et al. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. J Inf Secur. 2018;77(6):469–78.

    Google Scholar 

  8. Baya B, Achenbach CJ, Kone B, Toloba Y, Dabitao DK, Diarra B, et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect Dis. 2019;81:149–55.

    Article  PubMed  PubMed Central  Google Scholar 

  9. https://en.wikipedia.org/wiki/List_of_Chinese_administrative_divisions_by_population: .

  10. Mohd Shariff N, Shah SA, Kamaludin F. Previous treatment, sputum-smear nonconversion, and suburban living: the risk factors of multidrug-resistant tuberculosis among Malaysians. Int J Mycobacteriol. 2016;5(1):51–8.

    Article  PubMed  Google Scholar 

  11. Zhang C, Wang Y, Shi G, Han W, Zhao H, Zhang H, et al. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. BMC Public Health. 2016;16:42.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ladha N, Bhardwaj P, Chauhan NK, Naveen KHS, Nag VL, Giribabu D. Determinants, risk factors and spatial analysis of multi-drug resistant pulmonary tuberculosis in Jodhpur, India. Monaldi Arch Chest Dis. 2022;92(4)

  13. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380(9851):1406–17.

    Article  CAS  PubMed  Google Scholar 

  14. Ahmad AM, Akhtar S, Hasan R, Khan JA, Hussain SF, Rizvi N. Risk factors for multidrug-resistant tuberculosis in urban Pakistan: a multicenter case-control study. Int J Mycobacteriol. 2012;1(3):137–42.

    Article  PubMed  Google Scholar 

  15. Ullah I, Javaid A, Tahir Z, Ullah O, Shah AA, Hasan F, et al. Pattern of drug resistance and risk factors associated with development of drug resistant mycobacterium tuberculosis in Pakistan. PLoS One. 2016;11(1):e0147529.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 Clinical update by the global tuberculosis network. Int J Infect Dis. 2020;92S:S15–25.

    Article  PubMed  Google Scholar 

  17. Jacobs MG, Pelissari DM, Pinto VL. Factors associated with the drug-resistant tuberculosis incidence rate in Brazil. Int J Tuberc Lung Dis. 2018;22(6):675–80.

    Article  CAS  PubMed  Google Scholar 

  18. Alene KA, Viney K, McBryde ES, Gray DJ, Melku M, Clements ACA. Risk factors for multidrug-resistant tuberculosis in Northwest Ethiopia: a case-control study. Transbound Emerg Dis. 2019;66(4):1611–8.

    CAS  PubMed  Google Scholar 

  19. Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):219.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Badgeba A, Shimbre MS, Gebremichael MA, Bogale B, Berhanu M, Abdulkadir H. Determinants of multidrug-resistant mycobacterium tuberculosis infection: a multicenter study from southern Ethiopia. Infect Drug Resist. 2022;15:3523–35.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Alrajhi AA, Abdulwahab S, Almodovar E, Al-Abdely HM. Risk factors for drug-resistant mycobacterium tuberculosis in Saudi Arabia. Saudi Med J. 2002;23(3):305–10.

    PubMed  Google Scholar 

  22. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS One. 2010;5(12):e15735.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  23. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2):158–63.

    Article  CAS  PubMed  Google Scholar 

  24. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Inf Secur. 2018;77(6):469–78.

    Google Scholar 

  25. Bleich SN, Jarlenski MP, Bell CN, LaVeist TA. Health inequalities: trends, progress, and policy. Annu Rev Public Health. 2012;33:7–40.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Blom N, Huijts T, Kraaykamp G. Ethnic health inequalities in Europe. The moderating and amplifying role of healthcare system characteristics. Soc Sci Med. 2016;158:43–51.

    Article  PubMed  Google Scholar 

  27. LaVeist TA, Lebrun LA. Cross-country comparisons of racial/ethnic inequalities in health. J Epidemiol Community Health. 2010;64(01):7.

    Article  CAS  PubMed  Google Scholar 

  28. Lee EG, Min J, Kang JY, Kim SK, Kim JW, Kim YH, et al. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study. BMC Infect Dis. 2020;20(1):446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rifat M, Milton AH, Hall J, Oldmeadow C, Islam MA, Husain A, et al. Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors. PLoS One. 2014;9(8):e105214.

    Article  PubMed  PubMed Central  ADS  Google Scholar 

  30. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–70.

    Article  CAS  PubMed  Google Scholar 

  31. Law W, Yew W, Chiu Leung C, Kam K, Tam C, Chan C, et al. Risk factors for multidrug-resistant tuberculosis in Hong Kong. The international journal of tuberculosis and lung disease. 2008;12(9):1065–70.

    CAS  PubMed  Google Scholar 

  32. Song Q, Smith JP. Hukou system, mechanisms, and health stratification across the life course in rural and urban China. Health Place. 2019;58:102150.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kuang L, Liu L. Discrimination against rural-to-urban migrants: the role of the hukou system in China. PLoS One. 2012;7(11):e46932.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  34. Lecai J, Mijiti P, Chuangyue H, Mingzhen L, Qian G, Weiguo T, et al. Predictors and trends of MDR/RR-TB in Shenzhen China: a retrospective 2012–2020 period analysis. Infection and Drug Resistance. 2021;14:4481.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ge E, Li D, Luo M, Tsui K, Waye M, Shen X, et al. Transmission of multidrug-resistant tuberculosis in Shanghai: roles of residential status. The International Journal of Tuberculosis and Lung Disease. 2018;22(12):1462–8.

    Article  CAS  PubMed  Google Scholar 

  36. Lai P-C, Low CT, Tse WS, Tsui CK, Lee H, Hui PK. Risk of tuberculosis in high-rise and high density dwellings: an exploratory spatial analysis. Environ Pollut. 2013;183:40–5.

    Article  CAS  PubMed  Google Scholar 

  37. Hunan population density: https://en.wikipedia.org/wiki/Hunan:.

Download references

Acknowledgments

Not applicable.

Contributors/collaborators

Not Found.

Funding

KAA is funded by the Australian National Health and Medical Research Council (NHMRC) through an Emerging Leadership Investigator Grant APP1196549. TYA is also supported by Curtin University Higher Degree Research (HDR) Scholarship. The funders had no role in the study design, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. School of Population Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia

    Temesgen Yihunie Akalu & Kefyalew Addis Alene

  2. Geospatial and Tuberculosis Research Team, Telethon Kids Institute, Perth, Western Australia, Australia

    Temesgen Yihunie Akalu, Archie C. A. Clements & Kefyalew Addis Alene

  3. Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

    Temesgen Yihunie Akalu

  4. Penninsula Medical School, University of Plymouth, Plymouth, UK

    Archie C. A. Clements

  5. Xiangya School of Public Health, Central South University, Changsha, China

    Zuhui Xu

  6. TB Control Institute of Hunan Province, Changsha, China

    Liqiong Bai

Authors
  1. Temesgen Yihunie Akalu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Archie C. A. Clements
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zuhui Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liqiong Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kefyalew Addis Alene
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TYA, KAA, and ACAC conceived the study. TYA conducted a formal analysis and made the draft manuscript. ZX and LB collected the data and revised the drafted manuscript. Then ACAC and KAA advised on the data analysis and the development of the manuscript. All authors critically revised the manuscript for methodological and intellectual content and have read and approved the final manuscript.

Corresponding author

Correspondence to Temesgen Yihunie Akalu.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was obtained from Curtin University Human Research Ethics Committee (HRE2019-0581), and Hunan Province TB Control Institute granted written permission to access the data. Informed consent was waived by Hunan Tuberculosis Control Institute due to the retrospective nature of the data. All methodologies were carried out in accordance with the Declaration of Helsinki. Medical records of study subjects were de-identified to secure participants’ confidentiality. Besides, the soft copy was password protected to keep the patient’s confidentiality.

Consent for publication

Not required.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akalu, T.Y., Clements, A.C.A., Xu, Z. et al. Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study. BMC Infect Dis 24, 198 (2024). https://doi.org/10.1186/s12879-024-09106-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-024-09106-5

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us